PPT-SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED

1 ViiV Healthcare Brentford UK 2 Centre Hospitalier de Tourcoing Tourcoing France 3 Holdsworth House Medical Brisbane Queensland Australia 4 CHU SaintPierre Brussels Belgium 5. STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs) . HIV positive people in low- and middle-income countries including South Africa can be treated for around R900 (US $75 a year) . Massachusetts General Hospital. Boston, Massachusetts. State-of-the-ART in Antiretroviral Therapy: Optimal Initial Regimens in 2016. Washington, DC: August 23, 2016. Thanks to Alice Pau, Roger Bedimo and Marilyn Shi for assistance with slides. Treating and Preventing HIV in 2019: Interactive Cases From the Clinic(ians) Michael S. Saag , MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials Andrew Hill, Francois Venter, Eric Delaporte , Simiso Sokhela, Charles STARTMRK. GS-US-236-0102 . SINGLE. Walmsley. S. NEJM 2013;369:1807-18. Design. Objective. Non inferiority of DTG at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (1-sided significance level of 2.5%, lower margin of . QDMRK. SPRING-2. ONCEMRK. GS-US-380-1489. GS-US-380-1490. GS-US-380-1490. Design. Objective. Non inferiority of BIC/F/TAF at W48: % HIV RNA < 50 c/mL by intention . to treat, snapshot analysis (lower margin of the 2-sided 95.002% CI for . Medical Director, Specialty . Services. Southwest CARE Center. Santa Fe, New Mexico. State-of-the-ART. . in . Antiretroviral . Management. FORMATTED: MM/DD/YY. New Orleans, Louisiana: December 15-17, 2015. Geneva, March 19 - 20 , 2015 1 | Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato, Nathan Ford Update on CADO/PADO: what are the challenges in using the current guidelines an Joseph J. Eron, Jr, MD. Professor of Medicine. University of North Carolina. Chapel Hill, North Carolina. Panelists. Constance Benson. Hyman Scott. Annie . Luetkemeyer. Robert . Schooley. Financial Relationships With Commercial Entities. Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. ARV . strategies. DOR > DRV/r 1st line. (DRIVE-FORWARD W96). DTG. monotherapy. Switch PI/r-DTG (NEAT22). Switch RPV+DTG . (SWORD). Test and . Treat. D/C/F/TAF . (DIAMOND). −10% noninferiority margin for individual studies.. Andrew Hill, Francois Venter, Eric . Delaporte. , . Simiso. Sokhela, Charles . Kouanfack. , . Michelle Moorhouse. , Kaitlyn McCann, Bryony Simmons. , . Alexandra . Calmy. Disclosures. Speaker fees and honoraria from Gilead Sciences, AbbVie, Cipla, Johnson and Johnson, Sanofi, Pfizer, ViiV Healthcare, Mylan and Southern African HIV Clinicians Society. Associate Dean for Global Health. University of Alabama at Birmingham. Birmingham, Alabama. Cases from the Clinic(. ians. ): . Case. -based Panel Discussion. AU Final: 02/21/17. New York, New York: February 24, 2017.